This year, the annual congress of the European Society for Medical Oncology (ESMO) is taking place in Barcelona, Spain.
With the World Conference on Lung Cancer having wrapped up at the same venue just a couple of weeks ago, many conference delegates will no doubt have been tempted to schedule a late summer holiday in the city, rather than travel back and forth to attend both.
Those who are in attendance face a plethora of data to digest, with particular highlights in breast, ovarian, head and neck, lung and other cancers, spread over 280 sessions.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze